Company profile: Graniten
1.1 - Company Overview
Company description
- Provider of machine solutions for pharmaceutical manufacturing and healthcare automation, offering the Graniten Flexline modular packaging platform for high-mix, low-volume formats with near-zero changeover, TS230 case packer/palletizer, customized packaging and healthcare automation solutions (e.g., laboratory automation), and augmented reality remote support.
Products and services
- Healthcare Automation Solutions: Graniten architects facility-scale automation systems for healthcare facilities that improve efficiency and reduce manual labor, including laboratory automation systems
- TS230 Case Packer Palletizer: Graniten builds a compact, end-of-line pharmaceutical packaging system with automatic guide rail adjustment, 360° wrap-around taping, plus case and pallet aggregation
- Graniten Flexline Packaging Platform: Graniten engineers a modular packaging platform for high-mix, low-volume pharma production, enabling close-to-zero changeover across vials, bottles, syringes, and auto injectors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Graniten
Rebus Biosystems
HQ: United States
Website
- Description: Provider of spatial omics tools: Rebus Esper for single-cell data at subcellular resolution; Esper High Fidelity assay for spatial transcriptomics (up to 30 custom genes without barcoding or enzymatic amplification); Esper High Plex assay enabling analysis of 1230 gene panels; SAO microscopy enhancing resolution without sacrificing throughput; plus the Esper Service Program providing processed gene images and a spatially annotated CellxFeature matrix.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rebus Biosystems company profile →
Telo Genomics
HQ: Canada
Website
- Description: Provider of telomere-based platforms for biopsies and related technologies in oncology and neurological diseases. Offerings include TeloView, which quantifies genomic instability by measuring the 3D structure and spatial organization of telomeres to assess disease aggressiveness and treatment response, and TeloView SMM, a molecular assay identifying high-risk Smouldering Multiple Myeloma patients for treatment intervention decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telo Genomics company profile →
Sphere Fluidics
HQ: United Kingdom
Website
- Description: Provider of single cell analysis and characterization products, including Pico-Gen Biochips for generating picodroplets (60–1,000 picolitres), plus collaborative R&D services. Offers custom projects, application and technical support (monoclonality assurance, regulatory compliance), servicing and maintenance, and training on picodroplet-based microfluidic platforms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sphere Fluidics company profile →
Glympse Bio
HQ: United States
Website
- Description: Provider of noninvasive, predictive diagnostic solutions for monitoring multiple human diseases, using precisely engineered diagnostic agents that interrogate the body for disease states and carry the message to the urine for analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glympse Bio company profile →
Harbour Antibodies
HQ: United States
Website
- Description: Provider of transgenic mouse technology for engineering mice to produce high affinity human antibodies. Established in 2006, leveraging technology developed in the laboratory of Professor Frank Grosveld at Erasmus MC (Rotterdam, the Netherlands). The company has developed two types of human immunoglobulin gene transgenic mice.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harbour Antibodies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Graniten
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Graniten
2.2 - Growth funds investing in similar companies to Graniten
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Graniten
4.2 - Public trading comparable groups for Graniten
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →